XENON PHARMACEUTICALS INC. Retained Earnings
XENON PHARMACEUTICALS INC. (XENE) had Retained Earnings of -$1.46 billion as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-08-06
- 2026-06-30: Retained Earnings (Accumulated Deficit) -$1.46B.
- 2026-03-31: Retained Earnings (Accumulated Deficit) -$1.35B.
- 2025-12-31: Retained Earnings (Accumulated Deficit) -$1.25B.
- 2025-09-30: Retained Earnings (Accumulated Deficit) -$1.14B.
| Period end | Retained Earnings (Accumulated Deficit) | Retained Earnings (Accumulated Deficit) as first filed |
|---|---|---|
| 2026-06-30 | -$1.46B 10-Q · filed 2026-08-06 | |
| 2026-03-31 | -$1.35B 10-Q · filed 2026-05-07 | |
| 2025-12-31 | -$1.25B 10-Q · filed 2026-08-06 | |
| 2025-09-30 | -$1.14B 10-Q · filed 2025-11-03 | |
| 2025-06-30 | -$1.05B 10-Q · filed 2025-08-11 | |
| 2025-03-31 | -$964.52M 10-Q · filed 2025-05-12 | |
| 2024-12-31 | -$899.47M 10-K · filed 2026-02-26 | |
| 2024-09-30 | -$833.78M 10-Q · filed 2024-11-12 | |
| 2024-06-30 | -$771.00M 10-Q · filed 2024-08-08 | |
| 2024-03-31 | -$713.07M 10-Q · filed 2024-05-09 | |
| 2023-12-31 | -$665.14M 10-K · filed 2025-02-27 | |
| 2023-09-30 | -$620.40M 10-Q · filed 2023-11-08 | |
| 2023-06-30 | -$571.93M 10-Q · filed 2023-08-09 | |
| 2023-03-31 | -$524.47M 10-Q · filed 2023-05-09 | |
| 2022-12-31 | -$482.75M 10-K · filed 2024-02-29 | |
| 2022-09-30 | -$445.35M 10-Q · filed 2022-11-08 | |
| 2022-06-30 | -$408.20M 10-Q · filed 2022-08-09 | |
| 2022-03-31 | -$377.04M 10-Q · filed 2022-05-10 | |
| 2021-12-31 | -$357.37M 10-K · filed 2023-03-01 | |
| 2021-09-30 | -$331.81M 10-Q · filed 2021-11-10 | |
| 2021-06-30 | -$316.37M 10-Q · filed 2021-08-11 | |
| 2021-03-31 | -$294.26M 10-Q · filed 2021-05-11 | |
| 2020-12-31 | -$278.49M 10-K · filed 2022-03-01 | |
| 2020-09-30 | -$266.17M 10-Q · filed 2020-11-05 | |
| 2020-06-30 | -$257.31M 10-Q · filed 2020-08-06 | |
| 2020-03-31 | -$257.14M 10-Q/A · filed 2020-05-26 | |
| 2019-12-31 | -$249.66M 10-K · filed 2021-03-01 | |
| 2019-09-30 | -$238.28M 10-Q · filed 2019-11-05 | |
| 2019-06-30 | -$229.41M 10-Q · filed 2019-08-06 | |
| 2019-03-31 | -$219.40M 10-Q · filed 2019-05-07 | |
| 2018-12-31 | -$207.88M 10-K · filed 2020-03-09 | |
| 2018-09-30 | -$199.33M 10-Q · filed 2018-11-06 | |
| 2018-06-30 | -$184.94M 10-Q · filed 2018-08-07 | |
| 2018-03-31 | -$177.14M 10-Q · filed 2018-05-08 | |
| 2017-12-31 | -$173.39M 10-K · filed 2019-03-06 | |
| 2017-09-30 | -$165.32M 10-Q · filed 2017-11-07 | |
| 2017-06-30 | -$157.58M 10-Q · filed 2017-08-03 | |
| 2017-03-31 | -$150.20M 10-Q · filed 2017-05-09 | |
| 2016-12-31 | -$142.68M 10-K · filed 2018-03-07 | |
| 2016-09-30 | -$136.70M 10-Q · filed 2016-11-03 | |
| 2016-06-30 | -$128.97M 10-Q · filed 2016-08-03 | |
| 2016-03-31 | -$122.96M 10-Q · filed 2016-05-10 | |
| 2015-12-31 | -$119.69M 10-K · filed 2017-03-08 | |
| 2015-09-30 | -$115.75M 10-Q · filed 2015-11-10 | |
| 2015-06-30 | -$111.80M 10-Q · filed 2015-08-13 | |
| 2015-03-31 | -$112.93M 10-Q/A · filed 2015-08-13 | -$108.00M 10-Q · filed 2015-05-12 |
| 2014-12-31 | -$103.73M 10-K · filed 2016-03-08 | |
| 2014-09-30 | -$104.96M 10-Q · filed 2014-12-15 | |
| 2013-12-31 | -$116.75M 10-K · filed 2015-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 |